Determining the clinical course and outcome in chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 348, Issue 18, 2003, Pages 1797-1799

  Rai, Kanti R ^a   Chiorazzi, Nicholas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; PROTEIN P53; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; PATIENT CODING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRISOMY 12;

GENE EXPRESSION; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, T-CELL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 0037408455     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030032     Document Type: Editorial

References (14)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic ciassifi-classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
3. Galton DA. The pathogenesis of chronic lymphocytic leukemia. Can Med Assoc J 1966;94:1005-10.
4. Dameshek W. Chronic lymphocytic leukemia - an accumulative disease of immunologically incompetent lymphocytes. Blood 1967;29:Suppl:566-84.
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
6. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
7. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
8. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
9. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
10. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lym- phocytic leukemia. Blood 2002;100:4609-14.
11. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
12. Zupo S, Isnardi L, Megna M, et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996;88:1365-74.
13. H gene mutational status in chronic lymphocytic leukemia is associated with differential signaling via surface IgM. Blood 2002;100:99a. abstract.
14. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 2002;21:8541-6.